In silico study on β-aminoketone derivatives as thyroid hormone receptor inhibitors: a combined 3D-QSAR and molecular docking study

In order to explore the structure–activity correlation of a series of β-aminoketone analogs as inhibitors of thyroid hormone receptor (TR), a set of three-dimensional quantitative structure–activity relationship (3D-QSAR) models based on comparative molecular field analysis (CoMFA) and comparative molecular similarity analysis (CoMSIA), for the first time, were developed in the present work. The best CoMFA model with steric and electrostatic fields exhibited , for TRβ, and , for TRα. 3D contour maps produced from the optimal models were further analyzed individually, which provide the areas in space where interactive fields would affect the inhibitory activity. In addition, the binding modes of inhibitors at the active site of TRs were examined using molecular docking, the results indicated that this series of inhibitors fit into the active site of TRs by forming hydrogen bonding and electrostatic interactions. The docking studies also revealed that Leu305, Val458 for TRβ, and Asp407 for TRα are showing hydrogen bonds with the most active inhibitors. In any case, the 3D-QSAR models combined with the binding information will serve as a useful approach to explore the chemical space for improving the activity of TRβ and TRα inhibitors.

[1]  Jeong Hoon Kim,et al.  The roles of protein–protein interactions and protein methylation in transcriptional activation by nuclear receptors and their coactivators , 2003, The Journal of Steroid Biochemistry and Molecular Biology.

[2]  Á. Pascual,et al.  Nuclear hormone receptors and gene expression. , 2001, Physiological reviews.

[3]  N. Koibuchi,et al.  TRAM-1, A Novel 160-kDa Thyroid Hormone Receptor Activator Molecule, Exhibits Distinct Properties from Steroid Receptor Coactivator-1* , 1997, The Journal of Biological Chemistry.

[4]  R. Fletterick,et al.  Structural insight into the mode of action of a direct inhibitor of coregulator binding to the thyroid hormone receptor. , 2007, Molecular endocrinology.

[5]  C. Lyttle,et al.  A Transcriptional Coactivator, Steroid Receptor Coactivator-3, Selectively Augments Steroid Receptor Transcriptional Activity* , 1998, The Journal of Biological Chemistry.

[6]  K. Umesono,et al.  The nuclear receptor superfamily: The second decade , 1995, Cell.

[7]  R J Fletterick,et al.  Nuclear-receptor ligands and ligand-binding domains. , 1999, Annual review of biochemistry.

[8]  M Pastor,et al.  Reliability of comparative molecular field analysis models: effects of data scaling and variable selection using a set of human synovial fluid phospholipase A2 inhibitors. , 1997, Journal of medicinal chemistry.

[9]  J. Gasteiger,et al.  ITERATIVE PARTIAL EQUALIZATION OF ORBITAL ELECTRONEGATIVITY – A RAPID ACCESS TO ATOMIC CHARGES , 1980 .

[10]  Mukesh C. Sharma,et al.  Three-dimensional quantitative structure–activity relationship (3D-QSAR) analysis and molecular docking-based combined in silico rational approach to design potent and novel TRPV1 antagonists , 2012, Medicinal Chemistry Research.

[11]  P. Chambon,et al.  TIF2, a 160 kDa transcriptional mediator for the ligand‐dependent activation function AF‐2 of nuclear receptors. , 1996, The EMBO journal.

[12]  Thomas M. Mavromoustakos,et al.  Design of new secreted phospholipase A2 inhibitors based on docking calculations by modifying the pharmacophore segments of the FPL67047XX inhibitor , 2010, J. Comput. Aided Mol. Des..

[13]  Ling Yang,et al.  An in silico approach for screening flavonoids as P-glycoprotein inhibitors based on a Bayesian-regularized neural network , 2005, J. Comput. Aided Mol. Des..

[14]  V. Setola,et al.  Improvement of pharmacological properties of irreversible thyroid receptor coactivator binding inhibitors. , 2009, Journal of medicinal chemistry.

[15]  Yan Li,et al.  Docking, molecular dynamics and quantitative structure-activity relationship studies for HEPTs and DABOs as HIV-1 reverse transcriptase inhibitors , 2012, Journal of Molecular Modeling.

[16]  T. Tonoue,et al.  [Mechanism of thyroid hormone action]. , 1967, Saishin igaku. Modern medicine.

[17]  J D Baxter,et al.  The nuclear hormone receptor gene superfamily. , 1995, Annual review of medicine.

[18]  R. Zauhar,et al.  Computational studies on HIV-1 protease inhibitors: influence of calculated inhibitor-enzyme binding affinities on the statistical quality of 3D-QSAR CoMFA models. , 2000, Journal of medicinal chemistry.

[19]  Vincent Laudet,et al.  Principles for modulation of the nuclear receptor superfamily , 2004, Nature Reviews Drug Discovery.

[20]  H. Kubinyi.  Comparative Molecular Field Analysis (CoMFA) , 2002 .

[21]  Yonghua Wang,et al.  Structural requirements of pyrimidine, thienopyridine and ureido thiophene carboxamide-based inhibitors of the checkpoint kinase 1: QSAR, docking, molecular dynamics analysis , 2012, Journal of Molecular Modeling.

[22]  R. Evans,et al.  Nuclear Receptor Coactivator ACTR Is a Novel Histone Acetyltransferase and Forms a Multimeric Activation Complex with P/CAF and CBP/p300 , 1997, Cell.

[23]  B. O’Malley,et al.  Sequence and Characterization of a Coactivator for the Steroid Hormone Receptor Superfamily , 1995, Science.

[24]  Jianming Xu,et al.  Review of the in vivo functions of the p160 steroid receptor coactivator family. , 2003, Molecular endocrinology.

[25]  J. Chen,et al.  The SRC family of nuclear receptor coactivators. , 2000, Gene.

[26]  P. Corris,et al.  Atrial Septostomy and Transplantation for Patients with Pulmonary Arterial Hypertension , 2009, Seminars in respiratory and critical care medicine.

[27]  Yonghua Wang,et al.  A 3-D QSAR Study of Catechol-O-Methyltransferase Inhibitors Using CoMFA and CoMSIA , 2008 .

[28]  D. E. Patterson,et al.  Crossvalidation, Bootstrapping, and Partial Least Squares Compared with Multiple Regression in Conventional QSAR Studies , 1988 .

[29]  Ram Thaimattam,et al.  3D-QSAR studies on c-Src kinase inhibitors and docking analyses of a potent dual kinase inhibitor of c-Src and c-Abl kinases. , 2005, Bioorganic & medicinal chemistry.

[30]  Wei Yang,et al.  Structural analysis of selective agonists of thyroid hormone receptor β using 3D-QSAR and molecular docking , 2015 .

[31]  R J Fletterick,et al.  Hormone selectivity in thyroid hormone receptors. , 2001, Molecular endocrinology.

[32]  M. Lazar.  Thyroid hormone receptors: multiple forms, multiple possibilities. , 1993, Endocrine reviews.

[33]  R. Cramer,et al.  Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. , 1988, Journal of the American Chemical Society.

[34]  P. Goodford.  A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. , 1985, Journal of medicinal chemistry.

[35]  L. Martínez,et al.  Identification of a new hormone-binding site on the surface of thyroid hormone receptor. , 2014, Molecular endocrinology.

[36]  B. O’Malley,et al.  Molecular mechanisms of action of steroid/thyroid receptor superfamily members. , 1994, Annual review of biochemistry.

[37]  David S. Goodsell,et al.  Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998, J. Comput. Chem..

[38]  P. Meltzer,et al.  AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. , 1997, Science.

[39]  R. Cramer,et al.  Validation of the general purpose tripos 5.2 force field , 1989 .

[40]  R. Fletterick,et al.  Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships. , 2007, Journal of medicinal chemistry.

[41]  David M. Heery,et al.  A signature motif in transcriptional co-activators mediates binding to nuclear receptors , 1997, Nature.